Diagnosis, prevention and management of ovarian hyperstimulation syndrome

BJOG: An International Journal of Obstetrics & Gynaecology

Volumn 102, Issue 10, 1995, Pages 767-772

  Brinsden, P R ^a   Wada, I ^a   Tan, S L ^b   Balen, A ^c   Jacobs, H S ^d  

^a Bourn Hall Clinic ^*  (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANALGESIC AGENT; CHORIONIC GONADOTROPIN; GONADOTROPIN; HEPARIN;

CLINICAL FEATURE; FEMALE; HUMAN; OVARY HYPERSTIMULATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

FEMALE; HUMAN; OVARIAN HYPERSTIMULATION SYNDROME; PREVALENCE; RISK FACTORS;

EID: 0028787835     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1995.tb10840.x     Document Type: Review

References (48)

1. Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome
2. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome
3. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone
4. The management of predicted ovarian hyperstimulation involving gonadotrophin releasing hormone analog with elective cryo‐preservation of all pre‐embryos
5. Prevention of ovarian hyperstimulation syndrome
6. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups
7. The use of intravenous albumin in patients at risk for severe ovarian hyperstimulation syndrome
8. Miscarriage rates following in vitro fertilisation are increased in women with polycystic ovaries and reduced by pituitary de‐sensitisation with buserelin
9. Cumulative live birth rates after the treatment of anovulatory infertility: conception and safety and efficacy of ovulation induction in 200 patients
10. Ovarian hyperstimulation syndrome: A review of pathophysiology
11. In vitro fertilisation in infertile women with polycystic ovary syndrome
12. Triggering ovulation with endogenous luteinising hormone may prevent the ovarian hyperstimulation syndrome
13. Low‐dose gonadotropin regimes for induction of ovulation
14. Successful treatment of women with oligomenorrhoea using a combination of LHRH agonist and exogenous gonadotrophins
15. Severe ovarian hyperstimulation syndrome using agonists of gonadotrophin releasing hormone for in vitro fertilisation: a European series and a proposal for prevention
16. Ovarian hyperstimulation syndrome following D‐Trp6 luteinising hormone releasing hormone microcapsules and menotrophin for in vitro fertilisation
17. Ovarian hyperstimulation syndrome: an update review
18. Pregnancy rate and ovarian hyperstimulation syndrome after luteal human chorionic gonadotrophm for in vitro fertilisation stimulated with gonadotrophin releasing hormone analogue and menotrophins
19. Severe hyperstimulation syndrome and deep vein thrombosis
20. Avoidance of cancellation of potential hyperstimulation cycles by conversion to in vitro fertilisation‐embryo transfer
21. In vitro fertilisation and the ovarian hyperstimulation syndrome
22. A controlled study comparing patients with and without polycystic ovaries undergoing in vitro fertilisation
23. Adnexal torsion of hyperstimulated ovaries in pregnancies after gonadotrophin therapy
24. Luteal phase support and severe ovarian hyperstimulation
25. Accumulation of thromboxane B2 withln periovulatory ovine follicles: relationship to adhesion of platelets to endothelium
26. Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome
27. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment
28. The pathogenesis of ovarian hyperstimulation syndrome
29. Human menopausal gonadotrophins for anovulation and sterility
30. Severe ovarian hyperstimulation syndrome and cerebrovascular accidents
31. Treatment of hyperstimulation during in vitro fertilisation
32. Role of prostaglandins in ovarian hyperstimulation syndrome
33. Ovarian hyperstimulation syndrome: a current survey
34. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilisation program: a prospective, randomised, placebo‐controlled study
35. The role of luteal support in infertility treatment: a meta analysis of randomised trials
36. A prospective randomised study comparing aspiration only with aspiration and flushing for transvaginal ultrasound‐directed oocyte retrieval
37. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilisation: a prospective randomised study
38. Transvaginal peritoneal oocyte sperm transfer (POST) for the treatment of non‐tuba1 infertility
39. Treatment of severe hyperstimulation syndrome: the physiologic basis for a modified approach
40. Ovarian hyperstimulation syndrome in GnRH‐a/hMG cycles for IVF and GIFT
41. Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of developing the ovarian hyperstimulation syndrome
42. Is continuation of a gonadotrophin releasing hormone agonist (GnRH‐a) necessary for women at risk of developing ovarian hyperstimulation syndrome
43. Does elective cryopreservation of all embryos from women at risk of developing the ovarian hyperstimulation syndrome (OHSS) reduce the incidence of the condition
44. Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome
45. Prevention and treatment of ovarian hyperstimulation
46. Ovarian hyperstimulation in polycystic ovary syndrome during therapy with leuprolide acetate
47. The use of human menopausal gonadotrophins for induction of ovulation in women with polycystic ovarian syndrome
48. Adult respiratory distress syndrome complicating ovarian hyperstimulation